Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Sep 12 - Sep 17
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) demonstrate glucose-lowering, weight-reducing, and favourable anti-inflammatory and metabolic effects.1 These emerging drug classes have been proven to reduce cardiovascular events in patients with type 2 diabetes mellitus (T2DM) who are at high cardiovascular risk or have established cardiovascular disease.2 In this context, current guidelines recommend GLP-1RAs as first-line antidiabetic therapies in patients with established cardiovascular disease or high/very high cardiovascular risk.3 Semaglutide is a potent GLP-1RA used in the treatment of T2DM, with demonstrated cardiovascular benefits
Minimizing reactions: Tips for patients Patients can take several proactive steps to reduce the likelihood and severity of injection site reactions when using tirzepatide injection
Book your next appointment now
Some individuals report improvements in sexual function following significant weight reduction due to enhanced self-esteem, improved cardiovascular fitness, better hormonal balance, and reduced inflammation
This safety overview is not exhaustive and does not replace full prescribing information
Consider periodically retesting once-weekly dosing, perhaps every three to six months, to see whether you still need the split
US$ 24.88
US$ 26.59
US$ 24.68
US$ 27.26
US$ 26.19
